CRISPR-Cas has revolutionized the field of gene editing and will also disrupt the field of molecular diagnostics. CRISPR diagnostics (CRISPR-Dx), combined with a pre-amplification step, are faster and easier than (q)PCR whilst obtaining results of the same quality.

Sella Therapies is a clinical-stage medical device company developing a novel therapy for chronic pain relief that targets the body’s internal neuropeptide system.

Sencilia has developed a first-of-its-kind flow sensing device to reduce medication errors due to flow instabilities in intravenous infusions in neonates.

SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.

Providing a reliable UTI diagnosis and simultaneously indicating the optimal antibiotic prescription in under 4 hours

Sherwood Pharmaceuticals develops the first targeted therapy for Cri du Chat syndrome, repurposing safe small molecules to improve outcomes for patients with this rare genetic disorder.

Simplexable provides three-dimensional human scar models that are suitable for high content screening of compounds, targeting key events of hypertrophic scar formation.

The next generation of accurate and hassle-free tumor localization for breast cancer.

SLAM Ortho has developed an automated, accurate and fast bore depth measurement system for use in orthopaedic trauma procedures for fractures in extremities

Sniper Therapeutics enhances T-cell therapies for solid tumors by selecting and utilizing only tumor-killing T cells, resulting in more effective treatments.